Environment
day one project

Improving Federal Management of Wildlife Movement and Emerging Infectious Disease

10.20.20 | 6 min read | Text by Karen Lips

The COVID-19 pandemic has exposed systematic vulnerabilities in the way that wildlife movement and emerging infectious diseases are managed at national and international scales. The next administration should take three key steps to address these vulnerabilities in the United States. First, the White House should create a “Task Force on the Control of Emerging Infectious Diseases”. This Task Force would convene agencies with oversight over animal imports, identify necessary policy actions, determine priority research areas, and coordinate a national response strategy. Second, the next president should work with Congress to pass a bill strengthening live-animal import regulations. Third, U.S. agencies should coordinate with international organizations to address global movement of infectious diseases of animals. Together, these actions would reduce the risk of emerging infectious diseases entering the United States, offer greater protection to citizens from zoonotic diseases, and protect American biodiversity from losses due to wildlife diseases.

Challenge and Opportunity

More than 60% of emerging infectious diseases in humans first originate in animals. More than 70% of these come from wild animals. HIV, for instance, jumped to human hosts from primates in Africa. MERS spread to humans from camels in the Middle East. Of present salience, experts believe that the virus that causes COVID-19 originated from wild animals in China (probably bats).

The risk of animal-to-human “spillover”—and the global spread of zoonotic diseases—increases when wildlife are traded and imported around the world (e.g., for food, traditional medicines, display, pets, etc.). The global spread of COVID-19 has drawn attention to problems such as lack of disease surveillance in wild animal populations and lack of disease testing in many live animals at international borders. International wildlife-trade laws do not account for public-health risks of wildlife trade. These laws also do not require collection of data on zoonotic diseases (i.e., diseases caused by germs that spread between animals and people): data that could help prevent the next pandemic. These problems are exacerbated by accelerating rates of habitat conversion and biodiversity loss coupled with increased volume and speed of international commerce.

The United States is especially susceptible to emerging zoonotic diseases because it is the world’s largest importer6 of legally traded wild animals, yet lacks domestic regulations requiring most imported live animals to be tested for diseases, pathogens, or parasites. Gaps in U.S. statutory and regulatory frameworks governing live-animal imports increase disease risks for humans while also threatening our country’s biodiversity and natural resources. In the United States, four agencies oversee some aspect of live-animal imports—but this oversight is far from comprehensive. The Department of Agriculture’s Animal and Plant Health Inspection Service (APHIS) is responsible for assessing the risk of diseases in agricultural imports, but not wildlife species. The Center for Disease Control (CDC) oversees imports of only primates and some species of rodents, bats, or birds known to spread zoonotic diseases. The Fish and Wildlife Service (FWS) is responsible for regulating imports of all wildlife (and imposes stricter standards on species previously identified as injurious), but its mandate does not cover infectious diseases or parasites. The upshot is that imports of most wildlife species to the United States are not assessed for disease risk by any agency. Most disease agents that infect wildlife (except for a small number of known zoonotic diseases) are not monitored by any agency either.

Plan of Action 

The next administration should take three key steps to address systematic vulnerabilities in the way that wildlife movement and emerging infectious diseases are managed in the United States and around the world. 

Create a White House Task Force on the Control of Emerging Infectious Diseases.

This Task Force would convene agencies with oversight over animal imports (including the U.S. Department of Agriculture (USDA), the Department of the Interior (DOI), and CDC) and those supporting research (NSF, NIH) or international assistance (U.S. Department of State, USAID) to determine global research priorities on wildlife disease, and facilitate international cooperation on mechanisms to reduce demand as well as disease risk in the live animal trade. The task-force would use the One Health concept that links human health with animal health and environmental health, and that applies a comprehensive approach to understanding the drivers of disease emergence, the spread of disease, and the impacts on human health.

Work with Congress to pass a bill strengthening live-animal import regulations.

This bill would build on past legislation (e.g., H.R. 6362/S. 3210;11 H.R. 3771/S. 1903;12 and S. 375913) related to wildlife disease. The bill should:

Coordinate internationally to address diverse aspects of wildlife movement and emerging infectious diseases.

The next administration should direct USDA (primarily APHIS) and the FWS to lead the following efforts:

Conclusion 

Regulatory gaps put Americans at risk of exposure to emerging infectious disease from unregulated and under-regulated imports of wildlife. The next administration should address these gaps by creating a White House task force, strengthening live-animal import regulations, and coordinating with international institutions to reduce the global movement of emerging infectious diseases. The result would be a nation that is healthier and safer—for humans and animals alike.